Back to results

Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity In Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Objective

To determine in a randomized manner whether the addition of levocarnitine prophylaxis to asparaginase-containing regimens will decrease the incidence of conjugated hyperbilirubinemia (>3 mg/dL) during ALL induction therapy for adolescents and young adults (AYAs, age 15-39 years).

Protocol #

ACCL1931

Trial Phase:

Phase III

Principal Investigator:

Griffin, Jordyn

Cancer Type
  • Lymphoid Leukemia
  • Non-Hodgkin's Lymphoma
Study Site
  • Virginia Commonwealth University

Age: >/=15 and <40 years at time of diagnosis
Diagnosis: Newly Diagnosed B-ALL, T-ALL, Lymphoblastic Lymphoma (LLy), or Mixed-Phenotype Acute Leukemia/Lymphoma (MPAL)

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Both
  • Protocol Type Supportive Care
  • Research Study Team Lindsey Gwaltney, MS, RN
    Phone: +1 804-628-2112
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: